<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Medical Product Guide&#187; anastrozole</title>
	<atom:link href="http://blog.medicalproductguide.com/tag/anastrozole/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.medicalproductguide.com</link>
	<description>A comprehensive guide to medical products for medical professionals</description>
	<lastBuildDate>Mon, 20 Jun 2011 12:36:09 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>Roxane Receives FDA Approval For Anastrozole Tablets</title>
		<link>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/</link>
		<comments>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 19:14:49 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[FDA approvals]]></category>
		<category><![CDATA[Oncology products]]></category>
		<category><![CDATA[Pharmaceutical products]]></category>
		<category><![CDATA[anastrozole]]></category>
		<category><![CDATA[Anastrozole Tablets]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[ARIMIDEX]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Roxane Laboratories]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=454</guid>
		<description><![CDATA[Roxane Laboratories has received approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the FDA. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories&#8217; Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.]]></description>
			<content:encoded><![CDATA[<p>Roxane Laboratories has received approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the FDA. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories&#8217; Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Switching To Letrozole Helps Breast Cancer Patients With Anastrozole-Related Rheumatologic Symptoms</title>
		<link>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/</link>
		<comments>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 11:56:17 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[anastrozole]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[Postmenopausal]]></category>
		<category><![CDATA[SABCS]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=391</guid>
		<description><![CDATA[Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole therapy, researchers said at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). Women who experienced greater than equal to grade 2 A/M while receiving anastrozole and switched [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/01/Annual-San-Antonio-Breast-Cancer-Symposium3.png"><img class="alignright size-full wp-image-399" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/01/Annual-San-Antonio-Breast-Cancer-Symposium3.png" border="0" alt="Annual San Antonio Breast Cancer Symposium" width="200" height="117" /></a>Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole therapy, researchers said at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). Women who experienced greater than equal to grade 2 A/M while receiving anastrozole and switched to letrozole developed significantly less A/M and had an improved quality of life compared with baseline.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/174943.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Served from: blog.medicalproductguide.com @ 2012-05-26 06:27:03 -->
